Robert Alan Figler
12Patents
5h-index
11Co-inventors
59Inventor score
Filing activity: Oct 1, 2002 → Feb 22, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7576069B2 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | Chemistry; Metallurgy | 23 | Active |
| US7214665B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | Human Necessities | 19 | Expired |
| US7605143B2 | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity | Chemistry; Metallurgy | 15 | Active |
| US7442687B2 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | Chemistry; Metallurgy | 7 | Active |
| US7737127B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | Human Necessities | 5 | Active |
| US9617521B2 | In vitro model for a tumor microenvironment | Chemistry; Metallurgy | 5 | Active |
| US7875595B2 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | Chemistry; Metallurgy | 4 | Active |
| US7989431B2 | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity | Chemistry; Metallurgy | 3 | Active |
| US10221394B2 | In vitro model for a tumor microenvironment | Chemistry; Metallurgy | 1 | Active |
| US11008549B2 | In vitro model for a tumor microenvironment | Chemistry; Metallurgy | 0 | Active |
| US8158604B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | Human Necessities | 0 | Active |
| US8178509B2 | Method to treat sickle cell disease | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.